XML 33 R21.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Financial Instruments | 12 Months Ended
--- | ---
Dec. 31, 2024
Fair Value Disclosures [Abstract] |
Financial Instruments | I. FINANCIAL INSTRUMENTS Cash Equivalents Teradyne considers all highly liquid investments with maturities of three months or less at the date of acquisition to be cash equivalents. Marketable Securities Teradyne’s equity and debt mutual funds are classified as Level 1 and available-for-sale debt securities are classified as Level 2. The vast majority of Level 2 securities are fixed income securities priced by third party pricing vendors. These pricing vendors utilize the most recent observable market information in pricing these securities or, if specific prices are not available, use other observable inputs like market transactions involving identical or comparable securities. During the years ended December 31, 2024 and 2023, there were no transfers in or out of Level 1, Level 2, or Level 3 financial instruments. Realized gains recorded in 2024, 2023, and 2022 were $2.2 million, $0.6 million, and $0.8 million, respectively. Realized losses recorded in 2024, 2023, and 2022 were $0.3 million, $0.3 million, and $0.1 million, respectively. Realized gains and losses are included in other (income) expense, net. Unrealized gains on equity securities recorded during the years ended December 31, 2024, 2023 and 2022 were $6.7 million, $8.9 million and $1.9 million, respectively. Unrealized losses on equity securities recorded during the years ended December 31, 2024, 2023, and 2022 were $1.2 million, $1.7 million and $11.6 million, respectively. Unrealized gains and losses on equity securities are included in other (income) expense, net. Unrealized gains and losses on available-for-sale debt securities are included in accumulated other comprehensive income (loss) on the balance sheet. The cost of securities sold is based on average cost. The following table sets forth by fair value hierarchy Teradyne’s financial assets and liabilities that were measured at fair value on a recurring basis as of December 31, 2024 and 2023:
|  | December 31, 2024 |
|  | Quoted Prices in Active Markets for Identical Instruments (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |  |  | Total |
|  | (in thousands) |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 261,176 |  |  | $ | — |  |  | $ | — |  |  | $ | 261,176 |
Cash equivalents |  |  | 283,037 |  |  |  | 9,141 |  |  |  | — |  |  |  | 292,178 |
Available for sale securities: |  |  |  |  |  |  |  |  |  |  |  |
U.S. Treasury securities |  |  | — |  |  |  | 44,942 |  |  |  | — |  |  |  | 44,942 |
Corporate debt securities |  |  | — |  |  |  | 35,696 |  |  |  | — |  |  |  | 35,696 |
Certificates of deposit and time deposits |  |  | — |  |  |  | 21,689 |  |  |  | — |  |  |  | 21,689 |
Debt mutual funds |  |  | 8,951 |  |  |  | — |  |  |  | — |  |  |  | 8,951 |
U.S. government agency securities |  |  | — |  |  |  | 3,970 |  |  |  | — |  |  |  | 3,970 |
Non-U.S. government securities |  |  | — |  |  |  | 773 |  |  |  | — |  |  |  | 773 |
Equity securities: |  |  |  |  |  |  |  |  |  |  |  |
Mutual funds |  |  | 54,412 |  |  |  | — |  |  |  | — |  |  |  | 54,412 |
Total |  | $ | 607,576 |  |  | $ | 116,211 |  |  | $ | — |  |  | $ | 723,787 |
Derivative assets |  |  | — |  |  |  | 1,665 |  |  |  | — |  |  |  | 1,665 |
Total |  | $ | 607,576 |  |  | $ | 117,876 |  |  | $ | — |  |  | $ | 725,452 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Derivative liabilities |  |  | — |  |  |  | 1,324 |  |  |  | — |  |  |  | 1,324 |
Total |  | $ | — |  |  | $ | 1,324 |  |  | $ | — |  |  | $ | 1,324 |
Reported as follows: |  |  |  |  |  |  |  |  |  |  |  |
|  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |  |  | Total |
|  | (in thousands) |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 544,213 |  |  | $ | 9,141 |  |  | $ | — |  |  | $ | 553,354 |
Marketable securities |  |  | — |  |  |  | 46,312 |  |  |  | — |  |  |  | 46,312 |
Long-term marketable securities |  |  | 63,363 |  |  |  | 60,758 |  |  |  | — |  |  |  | 124,121 |
Other current assets |  |  | — |  |  |  | 1,665 |  |  |  | — |  |  |  | 1,665 |
Total |  | $ | 607,576 |  |  | $ | 117,876 |  |  | $ | — |  |  | $ | 725,452 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Other current liabilities |  | $ | — |  |  | $ | 1,324 |  |  | $ | — |  |  | $ | 1,324 |
Total |  | $ | — |  |  | $ | 1,324 |  |  | $ | — |  |  | $ | 1,324 |
|  | December 31, 2023 |
|  | Quoted Prices in Active Markets for Identical Instruments (Level 1) |  |  | Significant Other Observable Inputs (Level 2) |  |  | Significant Unobservable Inputs (Level 3) |  |  | Total |
|  | (in thousands) |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 298,156 |  |  | $ | — |  |  | $ | — |  |  | $ | 298,156 |
Cash equivalents |  |  | 453,298 |  |  |  | 6,117 |  |  |  | — |  |  |  | 459,415 |
Available for sale securities: |  |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities |  |  | — |  |  |  | 52,734 |  |  |  | — |  |  |  | 52,734 |
U.S. Treasury securities |  |  | — |  |  |  | 41,808 |  |  |  | — |  |  |  | 41,808 |
Certificates of deposit and time deposits |  |  | — |  |  |  | 21,772 |  |  |  | — |  |  |  | 21,772 |
Debt mutual funds |  |  | 8,773 |  |  |  | — |  |  |  | — |  |  |  | 8,773 |
U.S. government agency securities |  |  | — |  |  |  | 4,892 |  |  |  | — |  |  |  | 4,892 |
Commercial paper |  |  | — |  |  |  | 1,667 |  |  |  | — |  |  |  | 1,667 |
Non-U.S. government securities |  |  | — |  |  |  | 810 |  |  |  | — |  |  |  | 810 |
Equity securities: |  |  |  |  |  |  |  |  |  |  |  |
Mutual funds |  |  | 47,132 |  |  |  | — |  |  |  | — |  |  |  | 47,132 |
Total |  | $ | 807,359 |  |  | $ | 129,800 |  |  | $ | — |  |  | $ | 937,159 |
Derivative assets |  |  | — |  |  |  | 18,746 |  |  |  | — |  |  |  | 18,746 |
Total |  | $ | 807,359 |  |  | $ | 148,546 |  |  | $ | — |  |  | $ | 955,905 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Derivative liabilities |  |  | — |  |  |  | 2,545 |  |  |  | — |  |  |  | 2,545 |
Total |  | $ | — |  |  | $ | 2,545 |  |  | $ | — |  |  | $ | 2,545 |
Reported as follows: |  |  |  |  |  |  |  |  |  |  |  |
|  | (Level 1) |  |  | (Level 2) |  |  | (Level 3) |  |  | Total |
|  | (in thousands) |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 751,454 |  |  | $ | 6,117 |  |  | $ | — |  |  | $ | 757,571 |
Marketable securities |  |  | — |  |  |  | 62,154 |  |  |  | — |  |  |  | 62,154 |
Long-term marketable securities |  |  | 55,905 |  |  |  | 61,529 |  |  |  | — |  |  |  | 117,434 |
Other current assets |  |  | — |  |  |  | 18,746 |  |  |  | — |  |  |  | 18,746 |
Total |  | $ | 807,359 |  |  | $ | 148,546 |  |  | $ | — |  |  | $ | 955,905 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Other current liabilities |  | $ | — |  |  | $ | 2,545 |  |  | $ | — |  |  | $ | 2,545 |
Total |  | $ | — |  |  | $ | 2,545 |  |  | $ | — |  |  | $ | 2,545 |
The carrying amounts and fair values of Teradyne’s financial instruments at December 31, 2024 and 2023 were as follows:
|  | December 31, 2024 |  |  | December 31, 2023 |
|  | Carrying Value |  |  | Fair Value |  |  | Carrying Value |  |  | Fair Value |
|  | (in thousands) |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents |  | $ | 553,354 |  |  | $ | 553,354 |  |  | $ | 757,571 |  |  | $ | 757,571 |
Marketable securities |  |  | 170,433 |  |  |  | 170,433 |  |  |  | 179,588 |  |  |  | 179,588 |
Derivative assets |  |  | 1,665 |  |  |  | 1,665 |  |  |  | 18,746 |  |  |  | 18,746 |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |
Derivative liabilities |  |  | 1,324 |  |  |  | 1,324 |  |  |  | 2,545 |  |  |  | 2,545 |
The fair values of accounts receivable, net and accounts payable approximate the carrying amount due to the short-term nature of these instruments. The following tables summarize the composition of available-for-sale marketable securities at December 31, 2024 and 2023:
|  | December 31, 2024 |
|  | Available-for-Sale |
|  | Cost |  |  | Unrealized Gain |  |  | Unrealized (Loss) |  |  | Fair Market Value |  |  | Fair Market Value of Investments with Unrealized Losses |
|  | (in thousands) |
U.S. Treasury securities |  | $ | 49,879 |  |  | $ | 14 |  |  | $ | (4,951 | ) |  | $ | 44,942 |  |  | $ | 30,530 |
Corporate debt securities |  |  | 40,395 |  |  |  | 79 |  |  |  | (4,778 | ) |  |  | 35,696 |  |  |  | 27,824 |
Certificates of deposit and time deposits |  |  | 21,689 |  |  |  | — |  |  |  | — |  |  |  | 21,689 |  |  |  | — |
Debt mutual funds |  |  | 9,299 |  |  |  | — |  |  |  | (348 | ) |  |  | 8,951 |  |  |  | 3,238 |
U.S. government agency securities |  |  | 3,966 |  |  |  | 5 |  |  |  | (1 | ) |  |  | 3,970 |  |  |  | 1,946 |
Non-U.S. government securities |  |  | 773 |  |  |  | — |  |  |  | — |  |  |  | 773 |  |  |  | — |
|  | $ | 126,001 |  |  | $ | 98 |  |  | $ | (10,078 | ) |  | $ | 116,021 |  |  | $ | 63,538 |
Reported as follows:
|  | Cost |  |  | Unrealized Gain |  |  | Unrealized (Loss) |  |  | Fair Market Value |  |  | Fair Market Value of Investments with Unrealized Losses |
|  | (in thousands) |
Marketable securities |  | $ | 46,349 |  |  | $ | 16 |  |  | $ | (53 | ) |  | $ | 46,312 |  |  | $ | 10,454 |
Long-term marketable securities |  |  | 79,652 |  |  |  | 82 |  |  |  | (10,025 | ) |  | $ | 69,709 |  |  |  | 53,084 |
|  | $ | 126,001 |  |  | $ | 98 |  |  | $ | (10,078 | ) |  | $ | 116,021 |  |  | $ | 63,538 |
|  | December 31, 2023 |
|  | Available-for-Sale |
|  | Cost |  |  | Unrealized Gain |  |  | Unrealized (Loss) |  |  | Fair Market Value |  |  | Fair Market Value of Investments with Unrealized Losses |
|  | (in thousands) |
Corporate debt securities |  | $ | 56,458 |  |  | $ | 201 |  |  | $ | (3,925 | ) |  | $ | 52,734 |  |  | $ | 44,263 |
U.S. Treasury securities |  |  | 45,725 |  |  |  | 14 |  |  |  | (3,931 | ) |  |  | 41,808 |  |  |  | 35,080 |
Certificates of deposit and time deposits |  |  | 21,772 |  |  |  | — |  |  |  | — |  |  |  | 21,772 |  |  |  | — |
Debt mutual funds |  |  | 9,081 |  |  |  | — |  |  |  | (308 | ) |  |  | 8,773 |  |  |  | 3,303 |
U.S. government agency securities |  |  | 4,898 |  |  |  | — |  |  |  | (6 | ) |  |  | 4,892 |  |  |  | 4,892 |
Commercial paper |  |  | 1,633 |  |  |  | 34 |  |  |  | — |  |  |  | 1,667 |  |  |  | — |
Non-U.S. government securities |  |  | 810 |  |  |  | — |  |  |  | — |  |  |  | 810 |  |  |  | — |
|  | $ | 140,377 |  |  | $ | 249 |  |  | $ | (8,170 | ) |  | $ | 132,456 |  |  | $ | 87,538 |
Reported as follows:
|  | Cost |  |  | Unrealized Gain |  |  | Unrealized (Loss) |  |  | Fair Market Value |  |  | Fair Market Value of Investments with Unrealized Losses |
|  | (in thousands) |
Marketable securities |  | $ | 62,385 |  |  | $ | 36 |  |  | $ | (267 | ) |  | $ | 62,154 |  |  | $ | 34,844 |
Long-term marketable securities |  |  | 77,992 |  |  |  | 213 |  |  |  | (7,903 | ) |  | $ | 70,302 |  |  |  | 52,694 |
|  | $ | 140,377 |  |  | $ | 249 |  |  | $ | (8,170 | ) |  | $ | 132,456 |  |  | $ | 87,538 |
As of December 31, 2024, the fair market value of investments with unrealized losses less than one year and greater than one year totaled $22.6 million and $40.9 million, respectively. As of December 31, 2023, the fair market value of investments with unrealized losses less than one year and greater than one year totaled $22.3 million and $65.2 million, respectively. Teradyne reviews its investments to identify and evaluate investments that have an indication of possible impairment. Based on this review, Teradyne determined that the unrealized losses related to these investments at December 31, 2024 and 2023 were not other than temporary. The contractual maturities of investments in available-for-sale marketable securities held at December 31, 2024 were as follows:
|  | Cost |  |  | Fair Value |
|  | (in thousands) |
Due within one year |  | $ | 46,349 |  |  | $ | 46,312 |
Due after 1 year through 5 years |  |  | 25,554 |  |  |  | 25,316 |
Due after 5 years through 10 years |  |  | 8,648 |  |  |  | 8,232 |
Due after 10 years |  |  | 36,151 |  |  |  | 27,210 |
Total |  | $ | 116,702 |  |  | $ | 107,070 |
Contractual maturities of investments in available-for-sale marketable securities held at December 31, 2024 exclude debt mutual funds with the fair market value of $9.0 million as they do not have a contractual maturity date. Derivatives Teradyne conducts business in various foreign countries, with certain transactions denominated in local currencies. As a result, Teradyne is exposed to risks relating to changes in foreign currency exchange rates. Teradyne’s foreign currency risk management objective is to minimize the effect of exchange rate fluctuations associated with the remeasurement of monetary assets and liabilities denominated in foreign currencies, and changes in its cash inflows attributable to the forecasted cash flows from certain foreign currency denominated revenues. To minimize the effect of exchange rate fluctuations associated with the remeasurement of monetary assets and liabilities denominated in foreign currencies, Teradyne enters into foreign currency forward contracts. The change in fair value of these derivatives is recorded directly in earnings and is used to offset the change in value of monetary assets and liabilities denominated in foreign currencies. Teradyne also enters into foreign currency forward and option contracts designated as cash flow hedges to hedge the risk of changes in its cash inflows attributable to changes in foreign currency exchange rates. The cash flow hedges have maturities of less than six months and mature in the period of revenue recognition for certain products and services in backlog and forecasted to be recognized in a future period. Teradyne evaluates cash flow hedges for effectiveness at inception based on the critical terms match method. The hedges are not expected to incur any ineffectiveness however a quarterly qualitative assessment of effectiveness is done to determine if the critical terms match method remains appropriate to use. The change in fair value of the contracts is recorded in accumulated other comprehensive income (loss) and reclassified to earnings at maturity date. Teradyne does not use derivative financial instruments for speculative purposes. At December 31, 2024 and 2023, to hedge certain of its local currency balance sheet assets and liabilities, Teradyne had the following contracts to buy and sell non-U.S. currencies for U.S. dollars and other non-U.S. currencies with the following notional amounts:
|  | Net Notional Value |
|  | December 31, 2024 |  |  | December 31, 2023 |
|  | (in millions) |
Currency Hedged (Buy/Sell) |  |  |  |  |  |
U.S. dollar/Taiwan dollar |  | $ | 14.5 |  |  | $ | 42.7 |
U.S. dollar/Japanese yen |  |  | 12.6 |  |  |  | 11.0 |
Danish krone/Chinese yuan |  |  | 10.5 |  |  |  | — |
U.S. dollar/Korean won |  |  | 4.2 |  |  |  | 7.2 |
U.S. dollar/British pound sterling |  |  | 1.2 |  |  |  | 1.5 |
U.S. dollar/Danish krone |  |  | — |  |  |  | 36.0 |
Singapore dollar/U.S. dollar |  |  | 28.9 |  |  |  | 16.6 |
Euro/U.S. dollar |  |  | 22.3 |  |  |  | 25.3 |
Danish krone/U.S. dollar |  |  | 16.9 |  |  |  | 0.7 |
Philippine peso/U.S. dollar |  |  | 9.4 |  |  |  | 10.1 |
Chinese yuan/U.S. dollar |  |  | 1.6 |  |  |  | 1.0 |
|  | $ | 122.1 |  |  | $ | 152.1 |
The change in the fair value of the outstanding contracts was a loss of $0.6 million and a loss of $1.8 million, respectively, at December 31, 2024 and 2023. Unrealized gains and losses on foreign currency forward contracts and foreign currency remeasurement gains and losses on monetary assets and liabilities are included in other (income) expense, net. At December 31, 2024 and 2023, Teradyne had the following cash flow hedge contracts to buy and sell non-U.S. currencies for U.S. dollars with the following notional amounts:
|  | Net Notional Value |
|  | December 31, 2024 |  |  | December 31, 2023 |
|  | (in millions) |
Currency Hedged (Buy/Sell) |  |  |  |  |  |
U.S. dollar/Japanese yen |  | $ | 15.6 |  |  | $ | 35.5 |
Total |  | $ | 15.6 |  |  | $ | 35.5 |
The change in the fair value of the outstanding cash flow hedge contracts was a gain of $0.9 million at December 31, 2024 and a gain of $0.6 million at December 31, 2023. Unrealized gains and losses on foreign currency cash flow hedge contracts are included in accumulated other comprehensive income (loss). At maturity, the gains or losses associated with cash flow hedge contracts are recorded to revenue. On November 7, 2023, in connection with the agreement to acquire 10% investment in Technoprobe S.p.A, Teradyne purchased a call option to buy 481.0 million Euros. The expiration date of the option was April 26, 2024. At December 31, 2023, the fair value of the outstanding contract was $17.4 million and an unrealized gain of $7.5 million was recorded in other (income) expense, net. On April 12, 2024, Teradyne entered into a forward to buy 481.0 million Euros which expired on May 23, 2024. For the year ended December 31, 2024, a realized loss of $9.8 million was recorded in 'Other (income) expense, net' in the consolidated statement of operations. T he following table summarizes the fair value of derivative instruments as of December 31, 2024 and 2023:
|  | Balance Sheet Location |  | December 31, 2024 |  |  | December 31, 2023 |
|  |  |  | (in thousands) |
Derivatives not designated as hedging instruments: |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | Other current assets |  | $ | 725 |  |  | $ | 733 |
Foreign exchange option contracts |  | Other current assets |  |  | — |  |  |  | 17,364 |
Foreign exchange forward contracts |  | Other current liabilities |  |  | (1,324 | ) |  |  | (2,545 | )
Derivatives designated as hedging instruments: |  |  |  |  |  |  |  |
Foreign exchange forward contracts |  | Other current assets |  |  | 940 |  |  |  | 648 |
Total derivatives |  |  |  | $ | 341 |  |  | $ | 16,200 |
The following table summarizes the effect of derivative instruments in the statements of operations recognized for the years ended December 31, 2024, 2023, and 2022:
|  | Location of (Gains) Losses Recognized in Statement of Operations |  | December 31, 2024 |  |  | December 31, 2023 |  |  | December 31, 2022 |
|  |  |  | (in thousands) |
Derivatives not designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  |
Foreign exchange forward contracts (1) |  | Other (income) expense, net |  | $ | 3,226 |  |  | $ | (1,843 | ) |  | $ | (2,482 | )
Foreign exchange option contracts |  | Other (income) expense, net |  |  | 9,764 |  |  |  | (7,464 | ) |  |  | — |
Derivatives designated as hedging instruments: |  |  |  |  |  |  |  |  |  |  |
Foreign exchange forward and option contracts |  | Revenue |  |  | (2,402 | ) |  |  | (3,127 | ) |  |  | (251 | )
Total derivatives |  |  |  | $ | 10,588 |  |  | $ | (12,434 | ) |  | $ | (2,733 | )
(1) The table does not reflect the corresponding gains and losses from the remeasurement of the monetary assets and liabilities denominated in foreign currencies. For the years ended December 31, 2024, 2023 and 2022, net losses from remeasurement of monetary assets and liabilities denominated in foreign currencies were $2.8 million, $10.9 million, and $10.8 million, respectively. See Note K: “Debt” regarding derivatives related to the convertible senior notes. Concentration of Credit Risk Financial instruments which potentially subject us to concentrations of credit risk consist principally of cash equivalents, marketable securities, forward currency contracts and accounts receivable. Our cash equivalents consist primarily of money market funds invested in U.S. Treasuries and government agencies. Our fixed income available-for-sale marketable securities have a minimum rating of AA by one or more of the major credit rating agencies. We place forward currency contracts with high credit-quality financial institutions in order to minimize credit risk exposure. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of geographically dispersed customers. We perform ongoing credit evaluations of our customers’ financial condition and from time to time may require customers to provide a letter of credit from a bank to secure accounts receivable. As of December 31, 2024, two customers of our Semiconductor Test segment, Taiwan Semiconductor Manufacturing Co. and SK Hynix Inc, each accounted for 10% of our accounts receivable balance. As of December 31, 2023, a customer of our Semiconductor Test segment, Texas Instruments Inc., accounted for 18% of our accounts receivable balance.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration